Management of hypertension in chronic heart failure

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 4, 2009, Pages 423-433

  Manickavasagam, Saraswathy ^a   Merla, Ramanna ^a   Koerner, Michael M ^b   Fujise, Ken ^c   Kunapuli, Sanjay ^a   Rosanio, Salvatore ^a   Barbagelata, Alejandro ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b John Sealy Hospital and John Sealy Annex   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Congestive; Diastolic; Dysfunction; Heart failure; Hypertension; Systolic

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ETACRYNIC ACID; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; METOLAZONE; METOPROLOL; NITRATE; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; ANTIHYPERTENSIVE AGENT;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDICATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE RELAXATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MORTALITY; REVIEW; RISK FACTOR; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECT; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; HEART FAILURE; HUMANS; HYPERTENSION; RISK FACTORS; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67650311970     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.8     Document Type: Review

References (88)

1. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25-e146 (2008).
2. Liu L. A new epidemic of heart failure in the United States: findings from the National Hospital Discharge Survey, 1980-2006. Circulation 18, S1092 (2008).
3. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355(3), 260-269 (2006).
4. Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am. Heart J. 150(4), 701-706 (2005).
5. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
6. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur. Heart J. 20(11), 789-795 (1999).
7. Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24), 3068-3072 (2002).
8. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353(9169), 2008-2013 (1999).
9. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J. Hyperten. 20(4), 771-777 (2002).
10. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316(23), 1429-1435 (1987).
11. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. 344(18), 1351-1357 (2001).
12. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 99(20), 2658-2664 (1999).
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325(5), 293-302 (1991).
14. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325(5), 303-310 (1991).
15. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 40(8), 1414-1421 (2002).
16. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386), 772-776 (2003).
17. Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J. Am. Coll. Cardiol. 33(6), 1567-1572 (1999).
18. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359(23), 2456-2467 (2008).
19. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2095 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112(12), e154-e235 (2005).
20. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 364(9446), 1684-1689 (2004).
21. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am. J. Hypertens. 17(2), 118-123 (2004).
22. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366(9496), 1545-1553 (2005).
23. Khan N, McAlister FA. Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174(12), 1737-1742 (2006).
24. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann. Intern. Med. (1992) 117(6), 502-510.
25. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of β-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J. Am. Coll. Cardiol. 53(2), 184-192 (2009).
26. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334(21), 1349-1355 (1996).
27. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353(9146), 9-13 (1999).
28. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169), 2001-2007 (1999).
29. Manolis AJ, Olympios C, Sifaki M et al. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension 26(5), 719-724 (1995).
30. Manolis AJ, Olympios C, Sifaki M et al. Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure. Hypertension 29(1 Pt 2), 525-530 (1997).
31. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among Black and White subjects with resistant hypertension. Hypertension 40(6), 892-896 (2002).
32. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78(8), 902-907 (1996).
33. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol. 46(3), 425-431 (2005).
34. Baker DW. Prevention of heart failure. J. Card. Fail. 8(5), 333-346 (2002).
35. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 12(1), 10-38 (2006).
36. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
37. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328(13), 914-921 (1993).
38. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart failure in Type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (Type 2 Diabetes, Hypertension, Cardiovascular Events and Ramipril) study. Diabetes care 26(3), 855-860 (2003).
39. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342(3), 145-153.
40. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351(20), 2058-2068 (2004).
41. Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH - ESC Task Force on the Management of Arterial Hypertension. J. Hyperten. 25(9), 1751-1762 (2007).
42. Mayor S. NICE removes β blockers as first line treatment for hypertension. BMJ 333(7557), 8 (2006).
43. Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. β-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J. Am. Coll. Cardiol. 34(5), 1388-1394 (1999).
44. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462-1536 (2007).
45. Materson BJ, Reda DJ, Preston RA et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch. Intern. Med. 155(16), 1757-1762 (1995).
46. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).
47. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo - Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
48. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
49. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008).
50. Mak G, Murphy NF, Ali A et al. Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J. Card. Fail. 14(7), 555-560 (2008).
51. Poole-Wilson PA. ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Med. Clin. North Am. 87(2), 373-389 (2003).
52. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345(23), 1667-1675 (2001).
53. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9326), 767-771 (2003).
54. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitiors for left ventricular dysfuntion: a quantitative review of data from randomized cinilical trials. Arch. Intern. Med. 167(8), 1930-1936 (2008).
55. Brophy JM, Joseph L, Rouleau JL. β-blockers in congestive heart failure. A Bayesian meta-analysis. Ann. Intern. Med. 134(7), 550-560 (2001).
56. Goldstein S, Fagerberg B, Hjalmarson A et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J. Am. Coll. Cardiol. 38(4), 932-938 (2001).
57. Hensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am. J. Nephrol. 11(6), 441-446 (1991).
58. Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur. Heart J. 19(9), 1371-1376 (1998).
59. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31(1 Pt 2), 451-458 (1998).
60. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709-717 (1999).
61. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348(14), 1309-1321 (2003).
62. Beck L, Blanc-Guillemaud V, Cherif OK, Jover B, Davy JM. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology 96(2), 85-93 (2001).
63. Wu J, Kraja AT, Oberman A et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am. J. Hypertens. 18(7), 935-942 (2005).
64. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351(20), 2049-2057 (2004).
65. Taylor AL, Ziesche S, Yancy CW et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African - American Heart Failure Trial. Circulation 115(13), 1747-1753 (2007).
66. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335(15), 1107-1114 (1996).
67. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 96(3), 856-863 (1997).
68. Persson H, Lonn E, Edner M et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J. Am. Coll. Cardiol. 49(6), 687-694 (2007).
69. Brutsaert DL, Rademakers FE, Sys SU. Triple control of relaxation: implications in cardiac disease. Circulation 69(1), 190-196 (1984).
70. Kjeldsen SE, Dahlof B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288(12), 1491-1498 (2002).
71. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. (2003) 115(1), 41-46.
72. Wachtell K, Bella JN, Rokkedal J et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105(9), 1071-1076 (2002).
73. Solomon SD, Janardhanan R, Verma A et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369(9579), 2079-2087.
74. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 50(8), 768-777 (2007).
75. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am. J. Cardiol. 71(7), 602-604 (1993).
76. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc. Res. 28(12), 1863-1867 (1994).
77. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Warwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110(5), 558-565 (2004).
78. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J. Am. Coll. Cardiol. 22(1), 318-325 (1993).
79. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur. J. Heart Fail. 6(4), 453-461 (2004).
80. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215), 1575-1581 (2000).
81. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med. 327(10), 685-691 (1992).
82. Vantrimpont P, Rouleau JL, Wun CC et al. Additive beneficial effects of β-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J. Am. Coll. Cardiol. 29(2), 229-236 (1997).
83. Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc. Drugs Ther. 17(3), 257-263 (2003).
84. Flatner MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26(3), 215-225 (2005).
85. Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens. 20(1), 11-20 (2007).
86. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 49(11), 1157-1163 (2007).
87. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hyperten. 25(1), 217-226 (2007).
88. Recio-Mayoral A, Kaski JC, McMurray JJ, Horowitz J, van Veldhuisen DJ, Remme WJ. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc. Drugs Ther. 21(6), 459-465 (2007).